The sepsis diagnostics market is projected to grow at a CAGR of 10% during the forecast period, according to the latest market research report. In 2022, the global market size was valued at USD 632.5 million, and it is expected to reach USD 1491.4 million by 2030. The increasing prevalence of sepsis, a potentially fatal illness caused by the body’s reaction to infection, is one of the primary factors driving the market’s revenue growth. According to the World Health Organization (WHO), sepsis affects 30 million people globally every year and has a death rate of 20-30%. Sepsis is also a major cause of death in Intensive Care Units (ICUs) worldwide.
The market growth is further supported by factors such as the rise in geriatric populations, Hospital-Acquired Infections (HAIs), and an increase in surgical operations. The demand for accurate and efficient diagnostic tests for sepsis is also contributing to the market’s revenue growth. Early diagnosis is crucial for improving patient outcomes, reducing mortality rates, and minimizing the financial burden on healthcare systems. However, the gold standard for identifying sepsis is blood culture tests, which may take several days to produce results. As a result, there is a growing need for rapid diagnostic tests that can provide results within hours.
To meet this demand, manufacturers are developing and releasing new diagnostic tests such as Point-Of-Care (POC) tests, molecular diagnostics, and biomarker-based assays for sepsis. These tests provide quick and accurate results, enabling early diagnosis, timely treatment, and better patient outcomes. The sepsis diagnostics market is highly competitive, with key players such as Stryker Corporation, Medtronic, and Boston Scientific Corporation leading the way.
Get Free Sample PDF (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.reportsanddata.com/download-free-sample/2234
Segments Covered in the Report
The segmentation of the sepsis diagnostics market is based on various factors, including product type, technology, method, end-use, and regional outlook.
The product type outlook includes blood culture media, assay kits and reagents, instruments, software, and other products. Blood culture media is used for the growth and identification of microorganisms present in blood samples. Assay kits and reagents are used to detect sepsis-specific biomarkers in blood samples. Instruments such as automated blood culture systems and immunoassay analyzers are used for the diagnosis of sepsis. Software plays a crucial role in the analysis and interpretation of sepsis test results. Other products include sample collection and preparation kits.
The technology outlook includes microbiology, molecular diagnostics, immunoassays, flow cytometry, and other technologies. Microbiology involves the growth, identification, and characterization of microorganisms causing sepsis. Molecular diagnostics involve the detection of sepsis-specific genetic material using techniques such as Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS). Immunoassays involve the detection of sepsis-specific biomarkers using antibodies. Flow cytometry involves the identification and quantification of immune cells involved in the body’s response to sepsis.
The method outlook includes conventional and automated diagnostics. Conventional diagnostics involve manual processing of blood samples using techniques such as microscopy and culture. Automated diagnostics involve the use of automated blood culture systems, immunoassay analyzers, and other automated systems for the diagnosis of sepsis.
The end-use outlook includes hospitals, diagnostic laboratories, and other end-users such as research institutes and blood banks. Hospitals are the primary end-users of sepsis diagnostics due to the high prevalence of sepsis cases in hospitalized patients. Diagnostic laboratories provide specialized testing services for sepsis diagnosis and are increasingly adopting automated diagnostic systems.
The regional outlook includes North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America and Europe are the largest markets for sepsis diagnostics due to the high prevalence of sepsis and the availability of advanced healthcare infrastructure. The Asia Pacific region is expected to witness significant growth in the sepsis diagnostics market due to the increasing incidence of sepsis and the rising demand for rapid and accurate diagnostic tests. Latin America and the Middle East & Africa regions are also expected to offer lucrative growth opportunities for sepsis diagnostics market players.
Access Full Report Description with Research Methodology and Table of Contents @ https://www.reportsanddata.com/report-detail/sepsis-diagnostics-market
Strategic development:
The year 2020 saw the introduction of Abbott Laboratories’ ID NOW™, a point-of-care blood test for sepsis. This test provides highly accurate results within minutes, enabling early detection of sepsis and prompt treatment. Another notable launch in 2021 was Becton, Dickinson and Company’s BD Veritor™ Plus System, a rapid diagnostic test for sepsis that provides accurate results in only 15 minutes and can be used in a variety of settings, including hospitals and clinics.
In terms of strategic development, Thermo Fisher Scientific Inc. made a significant move by acquiring QIAGEN N.V. in 2020, a major provider of diagnostic solutions, including sepsis testing. The acquisition was aimed at expanding Thermo Fisher’s product offerings in the diagnostics market.
Danaher Corporation also made a significant acquisition in 2021 by acquiring Aldevron, a biotech company that specializes in the production of plasmid DNA, RNA, and proteins for gene and cell therapy, vaccines, and diagnostic markets. The acquisition was aimed at strengthening Danaher’s position in the diagnostics market, including sepsis diagnostics.
Furthermore, in 2020, Luminex Corporation obtained Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its NxTAG® CoV Extended Panel, a multiplexed molecular test that detects various respiratory viruses, including SARS-CoV-2, which can lead to sepsis. These strategic developments and launches are expected to drive the sepsis diagnostics market forward, meeting the demand for accurate and efficient diagnostic tests that offer timely and effective treatment to patients.
Competitive Landscape:
The sepsis diagnostics market is highly competitive, with several key players operating in the industry. Abbott Laboratories, a global healthcare company, launched a new point-of-care blood test for sepsis in 2020, called the ID NOW™. The test provides highly accurate results in minutes, enabling early detection of sepsis and prompt treatment. Becton, Dickinson and Company, another major player in the market, launched the BD Veritor™ Plus System, a rapid diagnostic test for sepsis that provides accurate results in just 15 minutes and can be used in various settings, including hospitals and clinics.
BioMérieux SA, Thermo Fisher Scientific Inc., and Danaher Corporation are also significant players in the sepsis diagnostics market. Thermo Fisher Scientific Inc. acquired QIAGEN N.V. in 2020, a leading provider of diagnostic solutions, including sepsis testing, aimed at expanding its product offerings in the diagnostics market. In 2021, Danaher Corporation acquired Aldevron, a biotech company specializing in the production of plasmid DNA, RNA, and proteins for gene and cell therapy, vaccines, and diagnostic markets, to strengthen its position in the diagnostics market, including sepsis diagnostics. BioMérieux SA is a leading provider of in-vitro diagnostic solutions, including sepsis diagnostics, while Luminex Corporation and Bruker Corporation specialize in developing innovative diagnostic solutions for various diseases.
Other significant players in the sepsis diagnostics market include Nanosphere Inc. and T2 Biosystems Inc., which are known for developing advanced diagnostic technologies and tests for sepsis. Finally, Roche Diagnostics International Ltd. is a leading provider of diagnostic solutions for various diseases, including sepsis. With intense competition among key players, the sepsis diagnostics market is expected to experience significant growth, driven by rising demand for accurate and efficient diagnostic tests for sepsis.
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2234
In conclusion, the global Sepsis Diagnostics Market is highly competitive, with a few major players dominating the market. These companies are actively involved in developing new technologies and products, investing in research and development, and engaging in strategic partnerships and collaborations to maintain their market share and drive revenue growth.
About Us:
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
